0.4375
0.55%
-0.0024
アフターアワーズ:
.44
0.0025
+0.57%
Altamira Therapeutics Ltd (CYTO) 最新ニュース
ARMISTICE CAPITAL, LLC Acquires New Stake in Altamira Therapeuti - GuruFocus.com
CYTO stock plunges to 52-week low, hitting $0.57 amid market challenges - Investing.com Australia
Here's Why Auris (CYTO) Is a Great 'Buy the Bottom' Stock Now - Nasdaq
Altamira Therapeutics and Nuance Pharma Enter Into Exclusive Licensing and Distribution Agreement for Bentrio in China and Additional Asian Markets - AsiaOne
Altamira Therapeutics faces Nasdaq delisting over share price - Investing.com India
Altamira Therapeutics Provides Update on Nasdaq Listing - The Manila Times
Altamira Therapeutics Faces Nasdaq Delisting - TipRanks
Altamira Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com UK
CYTO stock plunges to 52-week low, touches $0.65 By Investing.com - Investing.com South Africa
CYTO stock plunges to 52-week low, touches $0.65 - Investing.com India
Altamira Medica obtains extended ISO 13485 certification By Investing.com - Investing.com South Africa
Altamira Medica obtains extended ISO 13485 certification - Investing.com
Altamira Therapeutics Announces Extended ISO 13485 Quality - GlobeNewswire
Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray - StockTitan
Earnings call: Altamira Therapeutics focuses on RNA delivery growth By Investing.com - Investing.com Australia
Earnings call: Altamira Therapeutics focuses on RNA delivery growth - Investing.com
Altamira Therapeutics Ltd. (NASDAQ:CYTO) Q2 2024 Earnings Call Transcript - Insider Monkey
Altamira Therapeutics Ltd (CYTO) Q2 2024 Earnings Call Transcript Highlights: Key Financial and ... By GuruFocus - Investing.com Canada
Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results - GlobeNewswire
Nuance Pharma Announces Expansion of Bentrio License and Distribution Agreement with Altamira Therapeutics - Digital More
Nuance Pharma Announces Expansion of Bentrio License and Distribution Agreement with Altamira Therapeutics in East and South East Asia - The Manila Times
Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024 - GlobeNewswire
Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering - GlobeNewswire
Altamira Issues Pre-Funded Share Purchase Warrant - TipRanks
Altamira Therapeutics announces $4 million public offering - Investing.com India
Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering - The Bakersfield Californian
Altamira Therapeutics Announces Expansion of Bentrio - GlobeNewswire
Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with - The Bakersfield Californian
Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia - StockTitan
Trending tickers: latest investor updates on Microsoft, Bitcoin, Altamira and Ashtead - Yahoo Finance UK
Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11 - GlobeNewswire
REPEAT — Diamond Equity Research Releases Update Note on Altamira Therapeutics Ltd. (NASDAQ: CYTO) - ForexTV.com
Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark - Marketscreener.com
Altamira expands Bentrio distribution to Scandinavia - Investing.com
Altamira Therapeutics Announces Extension of Bentrio - GlobeNewswire
大文字化:
|
ボリューム (24 時間):